

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 October 2024 (24.10.2024)



(10) International Publication Number
WO 2024/220843 A8

(51) International Patent Classification:

A61K 31/335 (2006.01) A61K 31/445 (2006.01)
A61K 31/495 (2006.01) A61K 31/33 (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:

PCT/US2024/025468

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/460,764	20 April 2023 (20.04.2023)	US
PCT/US2023/031835		
	01 September 2023 (01.09.2023)	US
63/561,294	04 March 2024 (04.03.2024)	US
63/575,594	05 April 2024 (05.04.2024)	US

(71) Applicant: **AURON THERAPEUTICS, INC.** [US/US];
55 Chapel Street, Suite 102, Newton, Massachusetts 02458
(US).


(72) Inventors: **NEEF, James Anthony**; c/o Auron Therapeutics, Inc., 55 Chapel Street, Suite 102, Newton, Massachusetts 02458 (US). **MILLAN, David Simon**; c/o Auron Therapeutics, Inc., 55 Chapel Street, Suite 102, Newton, Massachusetts 02458 (US). **MCRINER, Andrew John**; c/o Auron Therapeutics, Inc., 55 Chapel Street, Suite 102, Newton, Massachusetts 02458 (US). **AXFORD, Jake Charles**; c/o Auron Therapeutics, Inc., 55 Chapel Street, Suite 102, Newton, Massachusetts 02458 (US).

(74) Agent: **BERTINO, Lauren E.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: TECHNOLOGIES TARGETING CELL STATES

(57) Abstract: Among other things, the present disclosure provides technologies targeting KAT2. In some embodiments, the present disclosure provides technologies for reducing levels of KAT2 polypeptides in various systems. In some embodiments, the present disclosure provides technologies for treating various diseases, disorders, or conditions, including those associated with a KAT2 polypeptide such as various cancers.



(A)




Figure 1
(CONTINUED)

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

19 December 2024 (19.12.2024)

(15) Information about Correction:

see Notice of 19 December 2024 (19.12.2024)